Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental drug trichostatin a tested for safety in tough blood cancers

NCT ID NCT03838926

Disease control Sponsor: Vanda Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study is testing whether a drug called trichostatin A is safe for people with blood cancers that have returned or not responded to standard treatments. About 42 adults will receive the drug through an IV to find the highest safe dose and watch for side effects. The goal is not to cure the cancer but to see if the drug can be tolerated and studied further.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
trichostatin A
What this could lead to
If successful, this could identify a safe dose of trichostatin A for further testing in blood cancer patients.
What could go wrong
This is a very early Phase 1 trial with only 42 participants, focused on safety, not effectiveness. The drug may not work against the cancer or could cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 42 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2018

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject is ≥ 18 years at the time of signing informed consent; * Confirmed malignant hematologic disease or lymphoid malignancy that has relapsed or is refractory to standard therapy and has exhausted all available therapies; * Presence of measurable or evaluable disease; * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2; * Contraceptives or other approved avoidance of pregnancy measures Exclusion Criteria: * Allogeneic stem cell transplant recipient presenting with graft versus host disease (GVHD) either active or requiring immunosuppression; * Concomitantly taking anti-cancer therapy (bisphosphonates are permitted); * Undergone major surgery ≤ 2 weeks prior to starting study drug; * Evidence of mucosal or internal bleeding; * Impaired cardiac function or conduction defect; * Concurrent severe and/or uncontrolled medical conditions

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Relapsed or refractory hematologic malignancies are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid system neoplasm neoplasm Recurrence refractory hematologic cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Relapsed or refractory hematologic malignancies

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    4 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Vanda Investigational Site

    WITHDRAWN

    Washington D.C., District of Columbia, 20007, United States

  • Vanda Investigational Site

    COMPLETED

    Lafayette, Indiana, 47905, United States

  • Vanda Investigational Site

    WITHDRAWN

    Hackensack, New Jersey, 07601, United States

  • Vanda Investigational Site

    COMPLETED

    Seattle, Washington, 98109, United States

  • Vanda Investigational Site

    RECRUITING

    Biała Podlaska, Poland

  • Vanda Investigational Site

    RECRUITING

    Katowice, Poland

  • Vanda Investigational Site

    COMPLETED

    Krakow, Poland

  • Vanda Investigational Site

    RECRUITING

    Opole, Poland

  • Vanda Investigational Site

    COMPLETED

    Skorzewo, Poland

  • Vanda Investigational Site

    RECRUITING

    Warsaw, Poland

  • Vanda Investigational Site

    COMPLETED

    Wroclaw, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.